NASDAQ$TXG
10X Genomics Inc · Q3 2025 earnings
Q3 2025 earnings · · After market close · Investor relations
Briefing
10x Genomics reported Q3 2025 revenue of $149.0M with a net loss of $27.5M ($0.22 per share).
Revenue was $149.0 million, roughly flat year over year, as Chromium and Xenium platforms faced mixed academic and biopharma demand. Net loss was $27.5 million, or $(0.22) per share.
- Q3 revenue $149.0M.
- Net loss $27.5M; EPS $(0.22).
- Single-cell and spatial biology instruments and consumables.
- Installed base and consumable pull-through drive recurring revenue.
Headline financials
Revenue & EPS history
10X Genomics · Revenue · Quarterly
$149M
Revenue by segment
10X Genomics · $149M total across 4 segments · Q3 2023
- Single Cell Consumables$100M—67.2%
- Spatial Instruments$22.7M—15.2%
- Spatial Consumables$14.1M—9.4%
- Single Cell Instruments$12.2M—8.2%
Forward guidance
The filing discusses 10x Genomics's outlook, capital priorities, and key risks, including guidance or operating targets where disclosed.
Tailwinds
- 10x Genomics cites execution and demand supporting the near-term outlook.
- Balance sheet and capital allocation remain focal points in the filing.
Headwinds
- GAAP profitability remained under pressure in the quarter.
- Macro, competition, and input costs may pressure margins quarter to quarter.
- One-time items and segment mix can affect comparability versus prior periods.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2025
+2.1%
Avg return
Earnings day
+2.3%
Avg return
5 days after
+2.0%
Avg return
30 days after
58%
15 / 26 earnings
Positive
+17.3%
Q3 2025
Best reaction
-21.9%
Q1 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.6% | -5.9% | +38.4% | |
| Q4 2025 | +3.5% | +11.8% | +7.3% | |
| Q3 2025 | +17.3% | +28.4% | +36.7% | |
| Q1 2025 | +1.3% | +5.7% | +9.2% | |
| Q4 2024 | -0.5% | +0.6% | -13.8% | |
| Q3 2024 | +4.0% | +3.0% | -2.4% | |
| Q2 2024 | +12.7% | +18.8% | +18.8% | |
| Q1 2024 | -5.2% | -3.2% | -21.1% | |
| Q4 2023 | +0.8% | -1.3% | -24.4% | |
| Q3 2023 | +15.7% | +13.7% | +33.3% | |
| Q2 2023 | -4.5% | -7.7% | -7.9% | |
| Q1 2023 | +5.9% | +5.5% | +5.7% | |
| Q4 2022 | +14.8% | +15.2% | +7.5% | |
| Q3 2022 | +13.0% | +9.5% | +38.1% | |
| Q2 2022 | +5.4% | +13.2% | -24.0% | |
| Q1 2022 | -0.5% | -6.4% | -10.6% | |
| Q4 2021 | -15.0% | -14.4% | -26.7% | |
| Q3 2021 | +12.7% | +7.7% | -14.9% | |
| Q2 2021 | -1.8% | -3.3% | +3.7% | |
| Q1 2021 | -21.9% | -27.1% | -2.6% | |
| Q4 2020 | -3.1% | -7.1% | -7.6% | |
| Q3 2020 | +1.8% | +3.3% | +11.4% | |
| Q2 2020 | +0.6% | +6.0% | +17.1% | |
| Q1 2020 | -0.4% | -6.0% | +3.1% | |
| Q4 2019 | -2.1% | -11.4% | -40.6% | |
| Q3 2019 | +3.1% | +10.3% | +17.3% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro